Sign In
Buy LLY
$1,116.11
-5.06 (-0.451%)
At Close: Aug 04, 2026
In the Phase 1b Heart-2 trial, a single intravenous infusion of VERVE-102 produced dose-dependent lowering of PCSK9 and LDL-C, with both reductions sustained over follow-up of up to 18 months in parti
Eli Lilly Just Made a Game-Changing Move in the Billion-Dollar Weight Loss Drug Space. Here's What You Need to Know.
05:05am, Monday, 25'th May 2026
Eli Lilly and Novo Nordisk have been vying for dominance in the weight loss drug market. Lilly has gradually surpassed Novo Nordisk, and it now holds 60% of the U.S. market.
Healthcare Stocks Are on Fire -- Don't Miss These Opportunities
04:41pm, Friday, 22'nd May 2026
Innovation, regulatory policy, and demographics are driving healthcare stocks higher. Healthcare companies have also posted strong first-quarter results.
LLY Reports Third Phase III Win for Next-Generation Obesity Drug
11:36am, Friday, 22'nd May 2026
Eli Lilly's retatrutide delivers its third phase III win, showing up to 28.3% weight loss at 80 weeks and broader gains across obesity-related measures.
Phase 3 LIBRETTO-432 study evaluating Retevmo (selpercatinib) as adjuvant therapy in RET fusion-positive NSCLC to be featured in the Plenary Session and ASCO press program Investigator-initiated study
Eli Lilly's Next-Gen Obesity Drug Delivers Eye-Popping Weight Loss
09:15am, Thursday, 21'st May 2026
Patients lost up to 85 pounds in a study of Eli Lilly's next-generation weight-loss drug, the company said Thursday.
Can Eli Lilly Stock Reach $1800 by 2030? Here Is the Bull Case
08:25am, Thursday, 21'st May 2026
Eli Lilly (NYSE:LLY | LLY Price Prediction) is growing like a software company.
Could Viking Therapeutics Be the Next Eli Lilly?
08:10am, Thursday, 21'st May 2026
Eli Lilly dominates the weight loss drug market and competes with fellow pharma giant Novo Nordisk. Viking is studying promising weight loss candidates in late-stage trials.
Eli Lilly's New Weight-Loss Treatment Shows Promising Results
07:10am, Thursday, 21'st May 2026
An investigational drug developed by Eli Lilly delivered clinically meaningful weight loss in a trial, the company said as it looks expand its obesity treatment portfolio amid soaring demand.
Patients on Lilly's next-gen obesity drug lost 28% of body weight, company says
06:47am, Thursday, 21'st May 2026
Eli Lilly said on Thursday that its experimental drug retatrutide helped patients diagnosed with obesity lose more than 28% of their weight over a year and a half in a key trial that helps pave the
Eli Lilly says next-generation weight loss drug clears crucial obesity trial
06:45am, Thursday, 21'st May 2026
Eli Lilly said its next-generation drug cleared a crucial late-stage trial in patients with obesity, delivering significant weight loss across doses. The results bring Lilly one step closer to filin
Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial
06:45am, Thursday, 21'st May 2026
In TRIUMPH-1, participants on 12 mg retatrutide lost an average of 70.3 lbs (28.3%) over 80 weeks with 45.3% of participants achieving ≥ 30% weight loss, a level long associated with bariatric surge
Focus: Lower cost Novo, Lilly weight-loss pills draw patients from compounded drugs, doctors say
06:02am, Thursday, 21'st May 2026
Lower prices for weight-loss pills from Novo Nordisk and Eli Lilly are prompting patients to switch from compounded medications to branded Wegovy and Foundayo, according to Reuters interviews with nin
Best Weight Loss Drug Stocks to Buy in 2026
11:15pm, Wednesday, 20'th May 2026
Demand for weight-loss drugs has exploded, with material differentiation among the players in the niche. There's a clear leader, but that may not be the best investment option for you in 2026.
Eli Lilly accuses church bishops, businessmen of fraud in Trulicity drug rebate scheme
10:58am, Wednesday, 20'th May 2026
Eli Lilly has disclosed in a civil lawsuit filed in federal court on Tuesday that a rebate fraud scheme cost it more than $200 million. The company alleges several bishops and a leader of the Church o
